Radiopharm Theranostics (RADX) directors revise stakes after 2026 option expiry

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd (RADX) reports, via a Form 6-K, that it has furnished to U.S. investors an announcement filed with the Australian Securities Exchange detailing changes in directors’ interests following the expiry of listed options expiring 24 Aug 2026 for four directors. The notices show updated direct and indirect holdings for Riccardo Canevari, Paul Hopper, Ian Turner and Hester Larkin in the company’s shares and options after these listed options expired.

Filing Explained

The filing records listed options expiring on August 24, 2026 and reports the directors’ post-expiry interests: Riccardo Canevari held 22,679,986 shares and 183,412,299 options; Paul Hopper 147,721,428 shares and 35,159,518 options; Ian Turner 9,985,292 shares and 22,027,348 options; and Hester Larkin 644,247 shares and 9,900,002 options.

Key Figures

Riccardo Canevari total shares after change: 22,679,986 shares Riccardo Canevari options after change: 183,412,299 options Paul Hopper total shares after change: 147,721,428 shares +5 more

8 metrics

Riccardo Canevari total shares after change 22,679,986 shares Total direct and indirect holdings after expiry of listed options (Exp 24 Aug 2026)

Riccardo Canevari options after change 183,412,299 options Options held after expiry of listed options (Exp 24 Aug 2026)

Paul Hopper total shares after change 147,721,428 shares Total direct and indirect holdings after expiry of listed options (Exp 24 Aug 2026)

Paul Hopper options after change 35,159,518 options Options held after expiry of listed options (Exp 24 Aug 2026)

Ian Turner total shares after change 9,985,292 shares Total direct and indirect holdings after expiry of listed options (Exp 24 Aug 2026)

Ian Turner options after change 22,027,348 options Options held after expiry of listed options (Exp 24 Aug 2026)

Hester Larkin total shares after change 644,247 shares Total direct and indirect holdings after expiry of listed options (Exp 24 Aug 2026)

Hester Larkin options after change 9,900,002 options Options held after expiry of listed options (Exp 24 Aug 2026)

Key Terms

Appendix 3Y, listing rule 3.19A.2, notifiable interest of a director, closed period

4 terms

Appendix 3Y regulatory

"Appendix 3Y Change of Director’s Interest Notice"

listing rule 3.19A.2 regulatory

"information under listing rule 3.19A.2 and as agent for the director"

notifiable interest of a director regulatory

"definition of “notifiable interest of a director” should be disclosed"

closed period regulatory

"traded during a +closed period where prior written clearance"

FAQ

What does Radiopharm Theranostics (RADX) report in this Form 6-K?

The Form 6-K furnishes an ASX announcement titled “Change of Director's Interest Notices x 4”, showing updated share and option holdings for four directors after the expiry of listed options expiring 24 Aug 2026.

Which Radiopharm Theranostics (RADX) directors are covered by the interest change notices?

The notices cover directors Riccardo Canevari, Paul Hopper, Ian Turner, and Hester Larkin, each with an Appendix 3Y detailing their direct and indirect share and option holdings after the option expiry.

How many shares and options does Riccardo Canevari hold in RADX after the change?

After the change, Riccardo Canevari holds 22,679,986 shares in total (20,029,986 direct and 2,650,000 indirect) and 183,412,299 options.

What are Paul Hopper’s post-change holdings in Radiopharm Theranostics (RADX)?

Paul Hopper holds 147,721,428 shares in total (53,900,000 direct and 93,821,428 indirect) and 35,159,518 options after the expiry of listed options expiring 24 Aug 2026.

What are Ian Turner’s updated share and option holdings in RADX?

Ian Turner holds 9,985,292 shares in total (2,530,595 direct and 7,454,697 indirect) and 22,027,348 options after the reported option expiry event.

What are Hester Larkin’s holdings in Radiopharm Theranostics (RADX) after the change?

Hester Larkin holds 644,247 shares in total (550,000 direct and 94,247 indirect) and 9,900,002 options following the expiry of the listed options on 24 Aug 2026.

Were the RADX director option changes made during a closed period?

For each director notice, it is stated that the interests were not traded during a closed period where prior written clearance was required, and the related clearance questions are marked N/A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/27/2026 - 08:00 AM Accepted by SEC EDGAR 08/27/2026 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 27, 2026 titled:

“Change of Director's Interest Notices x 4”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.

1

EXHIBITS

Exhibit Number		Description
99.1		Change of Director's Interest Notices x 4

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: August 27, 2026	By:	/s/ Amritha Sushil
		Amritha Sushil
		Company Secretary

3

Exhibit 99.1

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.             Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	19 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	24 August 2026
No. of securities held prior to change			Shares	Options
		Direct	20,029,986	185,287,299
		Indirect	2,650,000	-
		Total	22,679,986	185,287,299
Class	Listed Options
Number acquired	NIL
Number disposed	1,875,000 Listed Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	20,029,986	183,412,299
		Indirect	2,650,000	-
		Total	22,679,986	183,412,299
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options (Exp 24 Aug 2026)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.        Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	19 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	24 August 2026
No. of securities held prior to change			Shares	Options
		Direct	53,900,000	53,642,000
		Indirect	93,821,428	9,017,518
		Total	147,721,428	62,659,518
Class	Listed Options
Number acquired	NIL
Number disposed	27,500,000 Listed Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	53,900,000	26,142,000
		Indirect	93,821,428	9,017,518
		Total	147,721,428	35,159,518
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options (Exp 24 Aug 2026)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.             Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	31 March 2026

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Superannuation fund
Date of change	24 August 2026
No. of securities held prior to change			Shares	Options
		Direct	2,530,595	23,081,926
		Indirect	7,454,697	820,422
		Total	9,985,292	23,902,348
Class	Listed Options
Number acquired	NIL
Number disposed	Direct
	1,125 000 Listed Options
	Indirect
	750,000 Listed Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	2,530,595	21,956,926
		Indirect	7,454,697	70,422
		Total	9,985,292	22,027,348
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options (Exp 24 Aug 2026)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Appendix 3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.           Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Hester Larkin
Date of Last Notice:	18 December 2024

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	24 August 2026
No. of securities held prior to change			Shares	Options
		Direct	550,000	10,175,002
		Indirect	94,247	-
		Total	644,247	10,175,002
Class	Listed Options
Number acquired		NIL
Number disposed		275,000 Listed Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 1

Appendix 3Y

Change of Director’s Interest Notice

No. of securities held after change			Shares	Options
		Direct	550,000	9,900,002
		Indirect	94,247	-
		Total	644,247	9,900,002
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options (Exp 24 Aug 2026)

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.
Appendix 3Y Page 2	01/01/2011

Appendix 3Y

Change of Director’s Interest Notice

Part 3 – Closed period 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.
01/01/2011	Appendix 3Y Page 3

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 CHANGE OF DIRECTOR'S INTEREST NOTICES X 4 159.2 KB